Medigene AG

MDG1

DE000A1X3W00

Biotechnology & Medical Research

Market Closed - Xetra Other stock markets 11:36:24 2024-04-26 am EDT			5-day change	1st Jan Change
1.505 ^EUR	-5.64%		-21.61%	-1.31%

Apr. 25	Medigene AG Presents Streamlined 6-Day, High Stemness Tcr-T Therapy Production Process	CI
Apr. 08	Medigene AG Presents Favorable Safety Profile of TCR-T Cells with Costimulatory Switch Protein at AACR Annual Meeting 2024	CI

Medigene Ag Provides Earnings Guidance for 2024

March 28, 2024 at 02:30 am EDT

Medigene AG provided earnings guidance for 2024. For the year, company expects revenue to be between EUR 9 Million and 11 Million.

Latest news about Medigene AG

Medigene AG Presents Streamlined 6-Day, High Stemness Tcr-T Therapy Production Process	Apr. 25	CI
Medigene AG Presents Favorable Safety Profile of TCR-T Cells with Costimulatory Switch Protein at AACR Annual Meeting 2024	Apr. 08	CI
Medigene Gets European Patent for T-Cell Receptor Technology	Apr. 04	MT
Medigene AG Secures European Patent for Its iM-TCR Technology	Apr. 04	CI
Medigene AG Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Transcript : Medigene AG, 2023 Earnings Call, Mar 28, 2024	Mar. 28
Medigene Ag Provides Earnings Guidance for 2024	Mar. 28	CI
Medigene AG Expands Patent Portfolio in Japan for iM-TCR Technology to Directly Control TCR-T Safety and Efficacy	Mar. 04	CI
Medigene AG Announces Indication Selection for the Clinical Development of Its Lead 3Rd Generation Tcr-T Therapy Program in Solid Tumors	Feb. 12	CI
Medigene AG Maintains Financial Guidance for the Fiscal Year 2023	Nov. 21	CI
Medigene Presents New Data for MDG 2011, the First TCR in a Novel Kras Library	Nov. 04	CI
Medigene AG Presents First Pre-Clinical Data of Optimal Affinity TCR Targeting mKRAS G12V Combined with a PD1-41BB Costimulatory Switch Protein Showing	23-10-23	CI
Medigene to Present New Pre-Clinical Data for Pipeline TCR-T Therapies At the ESMO Congress 2023	23-10-16	CI
Medigene Expands Intellectual Property Rights for its Costimulatory Switch Proteins to Additional Immune Cell Types	23-08-23	CI
Medigene AG Provides Revenue Guidance for 2023	23-08-17	CI
Transcript : Medigene AG, H1 2023 Earnings Call, Aug 17, 2023	23-08-17
Medigene AG Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-16	CI
Medigene AG Presents Enhanced Tumor Cell Killing Effects upon Addition of PD1-41BB Switch Receptor to TCR-T Therapies	23-06-22	CI
Transcript : Medigene AG - Special Call	23-06-20
Medigene AG Announces Pipeline Expansion into Neoantigens with Programs Targeting Multiple KRAS Mutations and HLAs	23-06-01	CI
Medigene AG Presents the Web Tool Expitope 3.0 at the 20th Annual Meeting of the Association for Cancer Immunotherapy	23-05-04	CI
Medigene AG Maintains Guidance for the Fiscal Year 2023	23-05-03	CI
Medigene AG Presents Preclinical Data on MDG1015	23-04-18	CI
Medigene AG Enters Cooperative Research and Development Agreement with the National Cancer Institute to Evaluate the Use of Medigene’s Proprietary T Cell Receptors in Novel Cell Constructs	23-04-03	CI
Medigene AG Provides Earnings Guidance for the Year 2023	23-03-29	CI

Medigene AG is a Germany-based biotechnology company that develops treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. The Company focuses on the development of personalized T cell-based immunotherapies. It develops three platforms: T-cell receptor (TCR)-modified T cells for adoptive T-cell therapy as treatments for patients with tumor burdens; Dendritic cell (DC) vaccines for the treatment of low tumor burdens, such as minimal residual disease or for use in combination therapies, and T-cell-specific monoclonal antibodies (TABS) to identify T cells based on their T-cell receptors. The Company operates offices in Martinsried in Germany, as well as in Washington DC and San Diego in the United States.

Sector

Biotechnology & Medical Research

Calendar

2024-05-01 - Neoantigen International Summit

More about the company

Income Statement Evolution

More financial data

Ratings for Medigene AG

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.505 EUR

Average target price

2.675 EUR

Spread / Average Target

+77.74%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
MEDIGENE AG	-1.31%	39.46M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs

Medigene AG

Equities

MDG1

DE000A1X3W00

Biotechnology & Medical Research

Medigene Ag Provides Earnings Guidance for 2024

Latest news about Medigene AG

Chart Medigene AG

Company Profile

Income Statement Evolution

Ratings for Medigene AG

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs